Apixaban 2.5 MG Oral Tablet [ELIQUIS]

DRUG2 trials

Sponsors

Ottawa Hospital Research Institute, University Hospital, Geneva

Conditions

Deep Vein ThrombosisEssential Thrombocythemia (ET)JAK2 MutationMyeloproliferative Neoplasm (MPN)Polycythemia Vera (PV)Primary MyelofibrosisVenous Thromboembolism (VTE)

Phase 2

Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

CompletedNCT04243122

Ottawa Hospital Research InstituteEssential Thrombocythemia (ET), JAK2 Mutation, Myeloproliferative Neoplasm (MPN) +3

Start: 2021-02-17End: 2024-05-03Updated: 2024-05-29

Phase 3

The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis

Not yet recruitingNCT04981327

University Hospital, GenevaDeep Vein Thrombosis

Start: 2022-09-01End: 2027-08-31Target: 1300Updated: 2021-07-29

Related Papers

Assessing the Feasibility of Thromboprophylaxis with Apixaban in JAK2-Positive Myeloproliferative Neoplasm Patients: The Airport-MPN Trial

Blood2023-11-021 citations